+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global T-Cell Therapies Market - Distribution by Type of Therapy, Target Indications, Target Antigens, Key Players and Key Regions: Industry Trends and Global Forecasts, 2020-2030

  • ID: 5240431
  • Report
  • January 2021
  • Region: Global
  • 991 Pages
  • Roots Analysis
1 of 4

FEATURED COMPANIES

  • 5AM Ventures
  • BNH Investment
  • GC Pharma
  • LH Ventures
  • Osage University Partners
  • Steam Athena Capital
  • MORE

Overview

According to the World Health Organization (WHO), cancer is considered to be among the second leading causes of mortality worldwide, accounting for an estimated 10 million deaths annually. In fact, the global cancer burden is anticipated to increase by 70% in the next 20 years, exerting tremendous physical, emotional and financial strain on individuals, families, communities and health systems.  Although efforts are being made to develop safe and effective drugs for the treatment of different types of cancer, there is still a pressing need for more specific and potent drugs/therapies to combat this complex, life threatening clinical condition. Amidst the current initiatives to develop more targeted anti-cancer therapies, T-cell therapies (specifically CAR-T, TCR and TIL therapies) have emerged as a promising option owing to their capability to eradicate tumor cells from the body with minimal treatment-related side effects. These adoptive T-cell therapies (ACT) are based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. A number of chimeric antigen receptor T-cell (CAR-T) therapies, including KYMRIAH® (Novartis), YESCARTA® (Gilead Sciences) and TECARTUS™ (Gilead Sciences), have already been approved in the recent years validating the potential of such ACTs in cancer treatment. In addition to the industry stakeholders, more than 300 academic and research institutes, till date, have made significant contributions to this field, mostly by convening the initial research on potential therapy candidates. Prominent scientists, acting as key opinion leaders, are leading the clinical development efforts of more than 975 T-cell therapy candidates for the treatment of various oncological and non-oncological disorders. Several promising leads are anticipated to be commercially launched over the coming decade, following which the market is projected to grow at a substantial pace. 

It is also worth highlighting that capital investments worth over USD 17 billion have been made by various private and public sector investors during the last five years to fund the product development activity. In addition, there have been close to 350 recently reported instances of collaborations between industry/academic stakeholders to advance the development of various pipeline candidates. The ongoing research activity in this field has led to the discovery of several disease-specific targets, such as CD19, BCMA, CD22, CD20 and meso. Driven by the availability of innovative technology platforms, lucrative funding and encouraging clinical trial results, the T-cell immunotherapies market is poised for success in the long-run as multiple product candidates are expected to be approved over the coming decade.

Scope of the Report

The “Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (5th Edition) by Type of Therapy (CAR-T, TCR and TIL), Target Indications (Acute Lymphoblastic Leukemia, Non-Hodgkin’s Lymphoma, Melanoma, Bladder Cancer, Lung Cancer, Head and Neck Cancer, Multiple Myeloma, Sarcoma, Chronic Lymphocytic Leukemia, Ovarian Cancer, Esophageal Cancer, Colorectal Cancer, Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, Acute Myeloid Leukemia and Renal Cell Carcinoma), Target Antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Global Forecast 2020-2030” report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry. 

Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape of T-cell immunotherapies with respect to type of product (CAR-T, TCR and TIL), type of developer (industry/non-industry), phase of development (preclinical, phase I, phase I/II, phase II, phase III and approved), therapeutic area (hematological cancer, solid tumor and others), target therapeutic indication (non-Hodgkin lymphoma, acute lymphoblastic leukemia, multiple myeloma, brain cancer, acute myeloid leukemia, melanoma, lung cancer, ovarian cancer, liver cancer, pancreatic cancer, chronic lymphocytic leukemia, stomach cancer, breast cancer, sarcoma, mantle cell lymphoma, mesothelioma, colorectal cancer, bladder cancer and others), key target antigen (CD19, BCMA, CD22, CD20, Meso, GD2, CD38, CD123, CD30, HER2, GPC3, CD33 and CD13), source of T-cells (autologous/allogeneic), route of administration (intravenous, intratumor, intraperitoneal, intrapleural, intraventricular and others), dose frequency (single dose, multiple dose and split dose), patient segment (children, adults and seniors), and type of therapy (monotherapy and combination therapy). Further, the chapter provides a list of the most active players (in terms of number of pipeline candidates) and an insightful logo landscape, highlighting product developers in North America, Europe and the Asia Pacific.
  • Detailed profiles of marketed and mid- to late stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
  • An analysis of the CAR constructs of clinical-stage CAR-T therapies based on the generation of CAR-T therapy (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of vector (lentivirus, retrovirus, mRNA and other vectors) and type of co-stimulatory domain used.
  • An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2×2 matrix assessing the relative experience of KOLs shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field, and a schematic world map representation, indicating the geographical locations of eminent scientists/researchers involved in the development of T-cell therapies.
  • An analysis of the various CAR-T cell therapy focused clinical trials registered across the world, between 2009 and 2019, highlighting the year wise trend of initiation of such studies and distribution across different geographies. In addition, we have provided a detailed list of factors that have influenced the growth of CAR-T therapies, especially in China.
  • An overview of the various focus therapeutic areas of therapy developers, including an assessment of the opportunity (in terms of revenue generation potential from therapy sales) across oncological and non-oncological disease indications.
  • A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers, and a relative competitiveness analysis of different gene editing platforms (used for the development of T-cell therapies), based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.
  • An analysis of the partnerships that have been established in the recent past, covering R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
  • An analysis of the investments that have been made into companies that have proprietary T-cell based products/technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
  • A case study on other T-cell based therapies, apart from CAR-Ts, TCRs and TILs, including a detailed analysis of approved/pipeline products, featuring information on current phase of development, target therapeutic area(s), type of T-cells used and source of T-cells.
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models/approaches that a pharmaceutical company may choose to adopt to decide the price of a T-cell based immunotherapy that is likely to be marketed in the coming years.
  • An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter, highlighting the yearly trend of tweets, most frequently talked about product candidates, popular disease indications, target antigens, and prolific authors and social media influencers.
  • A review of the key promotional strategies that have been adopted by the developers of the marketed T-cell therapies, namely KYMRIAH® and YESCARTA®.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for T-cell immunotherapies over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2020-2030. The report also includes likely sales forecasts of T-cell immunotherapies that have been already commercialized or are in the late stages of development. Additionally, it features market size projections for the overall T-cell immunotherapies market, wherein both the current and upcoming opportunity is segmented across [A] type of therapy (CAR-T, TCR and TIL), [B] target indications (acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, melanoma, bladder cancer, lung cancer, head and neck cancer, multiple myeloma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, acute myeloid leukemia, and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others) and [D] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. 

The report features detailed transcripts of interviews held with the following individuals:

  • Tim Oldham (Chief Executive Officer, Cell Therapies)
  • Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
  • Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
  • Miguel Forte (Chief Operating Officer, TxCell)
  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Peter Ho (Director, Process Development, Iovance Biotherapeutics)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
  • Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
  • Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)
  • Patrick Dougherty (SVP, Strategy, Planning and Operations, Windmil Therapeutics)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • What are the prevalent R&D trends related to T-cell immunotherapies?
  • What are the key therapeutic areas for which T-cell immunotherapies are being/have been developed?
  • What are the challenges faced by stakeholders engaged in this domain?
  • Who are the leading industry and non-industry players in this market?
  • In which geographies an extensive research on T-cell immunotherapy is being conducted?
  • Who are the key investors in this domain? 
  • Who are the key opinion leaders/experts in this upcoming field of therapeutics?
  • What kind of partnership models are commonly adopted by industry stakeholders? 
  • What kind of contract manufacturing support is available for T-cell therapies, across different regions?
  • What kind of promotional strategies are likely to be adopted for T-cell therapies that are approved and commercialized in future?
  • What are the factors that are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments? 
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 5AM Ventures
  • BNH Investment
  • GC Pharma
  • LH Ventures
  • Osage University Partners
  • Steam Athena Capital
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1. Activation and Suppression Immunotherapy
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell-based Therapies
3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.6.5.1. Retroviral Vectors
3.6.5.2. Lentiviral Vectors
3.6.5.3. Non-viral Transfection Methods
3.7. Chimeric Antigen Receptor T-Cell Therapy (CAR-T)
3.7.1. History of Development
3.7.2. Anatomical Layout of CAR
3.7.2.1. Ectodomain
3.7.2.2. Transmembrane (TM) Domain
3.7.2.3. Endodomain
3.7.3. Development of CAR-T Cells
3.7.4. Universal CAR-T Cells
3.7.5. Route of Administration of CAR-T Cell Therapies
3.7.6. Case Study: CD19 CAR-T Cell Therapies
3.7.6.1. Other Important Biological Targets for CAR Development
3.7.7. Challenges Associated with CAR-T Cell Therapies
3.7.7.1. Competitive Risks
3.7.7.2. Clinical Risks
3.7.7.3. Regulatory Risks
3.7.7.4. Commercial Risks
3.8. T-Cell Receptor (TCR)-based Cell Therapy
3.8.1. History of Development
3.8.2. Anatomical Layout of TCR
3.8.3. Development of TCR for Therapy
3.8.4. Differences between CAR-T and TCR-based Therapies
3.9. Tumor Infiltrating Lymphocyte (TIL)-based Therapy
3.9.1. History of Development
3.9.2. Development of TILs for Therapy
3.10. Key Challenges and Roadblocks
3.11. Concluding Remarks

4. EMERGING TRENDS ON SOCIAL MEDIA
4.1. Chapter Overview
4.2. T-Cell Immunotherapies: Trends on Twitter
4.2.1. Historical Trend in Volume of Tweets
4.2.2. Trending Words / Phrases on Twitter
4.2.3. Most Popular Drugs on Twitter
4.2.4. Most Prolific Authors on Twitter
4.2.5. Most Popular Indications and Target Antigens

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. T-Cell Immunotherapies: Overall Market Overview
5.2.1. Analysis by Type of Product
5.3. CAR-T Cell Therapies: Overall Market Overview
5.3.1. Analysis by Type of Developer
5.3.2. Analysis by Phase of Development
5.3.3. Analysis by Therapeutic Area
5.3.4. Analysis by Popular Target Indications
5.3.5. Analysis by Popular Target Antigens
5.3.6. Analysis by Source of T-Cells
5.3.7. Analysis by Route of Administration
5.3.8. Analysis by Dose Frequency
5.3.9. Analysis by Patient Segment
5.3.10. Analysis by Type of Therapy
5.3.11. Key Industry Players: Analysis by Number of CAR-T Cell Therapies in Development
5.3.12. Key Non-Industry Players: Analysis by Number of CAR-T Cell Therapies in Development
5.4. TCR-based Therapies: Overall Market Overview
5.4.1. Analysis by Type of Developer
5.4.2. Analysis by Phase of Development
5.4.3. Analysis by Therapeutic Area
5.4.4. Analysis by Popular Target Indications
5.4.5. Analysis by Popular Target Antigens
5.4.6. Analysis by Source of T-Cells
5.4.7. Analysis by Route of Administration
5.4.8. Analysis by Dose Frequency
5.4.9. Analysis by Patient Segment
5.4.10. Analysis by Type of Therapy
5.4.11. Key Industry Players: Analysis by Number of TCR-based Therapies in Development
5.4.12. Key Non-Industry Players: Analysis by Number of TCR-based Therapies in Development
5.5. TIL-based Therapies: Overall Market Overview
5.5.1. Analysis by Type of Developer
5.5.2. Analysis by Phase of Development
5.5.3. Analysis by Therapeutic Area
5.5.4. Analysis by Popular Target Indications
5.5.5. Analysis by Source of T-Cells
5.5.6. Analysis by Route of Administration
5.5.7. Analysis by Dose Frequency
5.5.8. Analysis by Patient Segment
5.5.9. Analysis by Type of Therapy
5.5.10. Key Industry Players: Analysis by Number of TIL-based Therapies in Development
5.5.11. Key Non-Industry Players: Analysis by Number of TIL-based Therapies in Development

6. KEY INSIGHTS
6.1. Chapter Overview
6.2. T-Cell Immunotherapies: Competitive Analysis by Popular Target Antigens
6.2.1. Popular Targets Related to Haematological Malignancies
6.2.1.1. Competitive Landscape of CD19 CAR-T Cell Therapies
6.2.1.2. Clinical Trial Results of Prominent CD19 CAR-T Cell Therapies
6.2.1.3. Competitive Landscape of BCMA CAR-T Cell Therapies
6.2.1.4. Clinical Trial Results of Prominent BCMA CAR-T Cell Therapies
6.2.2. Solid Tumors: Popular Targets
6.2.2.1. Competitive Landscape of Meso CAR-T Cell Therapies
6.2.2.2. Clinical Trial Results of Prominent Meso CAR-T Cell Therapies
6.2.2.3. Competitive Landscape of GD2 CAR-T Cell Therapies
6.2.2.4. Clinical Trial Results of Prominent GD2 CAR-T Cell Therapies
6.3. T-Cell Immunotherapies: Key Opinion Leaders
6.3.1. CAR-T Cell Therapies: Key Opinion Leaders
6.3.2. CAR-T Cell Therapies: Most Prominent Key Opinion Leaders
6.3.3. TCR-based Therapies: Key Opinion Leaders
6.3.4. TCR-based Therapies: Most Prominent Key Opinion Leaders
6.3.5. TIL-based therapies: Key Opinion Leaders
6.3.6. TIL-based Therapies: Most Prominent Key Opinion Leaders
6.4. T-Cell Immunotherapies: CAR Construct Analysis
6.4.1. Analysis by Generation of CAR
6.4.2. Analysis by Type of scFv Antibody
6.4.3. Analysis by Type of Vector
6.4.4. Analysis by Type of Co-Stimulatory Domain(s)

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. CAR-T Cell Therapies: Clinical Trial Analysis
7.2.1. Methodology
7.2.2. Analysis by Trial Registration Year
7.2.3. Geographical Analysis by Number of Registered Trials
7.2.4. Case Study: CAR-T Cell Therapy Market in China
7.2.4.1. Factors Contributing to the Growth of CAR-T Cell Therapy Trials in China

8. CAR-T CELL THERAPY PROFILES
8.1. Chapter Overview
8.2. KYMRIAH® / Tisagenlecleucel / CTL019 (Novartis)
8.2.1. Therapy Overview
8.2.2. Current Development Status
8.2.3. Key Clinical Trial Results
8.2.4. Dosage Regimen, Price and Manufacturing
8.3. YESCARTA® / Axicabtagene Ciloleucel / KTE-C19 (Kite Pharma)
8.3.1. Therapy Overview
8.3.2. Current Development Status
8.3.3. Key Clinical Trial Results
8.3.4. Dosage Regimen, Price and Manufacturing
8.4. Tecartus / Brexucabtagene Autoleucel (Kite Pharma)
8.4.1. Therapy Overview
8.4.2. Current Development Status
8.4.3. Key Clinical Trial Results
8.4.4. Dosage Regimen, Price and Manufacturing
8.5. JCAR (Juno Therapeutics)
8.5.1. Therapy Overview
8.5.2. Current Development Status
8.5.3. Key Clinical Results
8.5.3.1. JCAR014
8.5.3.2. JCAR017
8.5.3.3. JCAR018
8.5.3.4. JCARH125
8.5.4. Dosage Regimen and Manufacturing
8.6. Idecabtagene Vicleucel / bb2121 (bluebird bio / Celgene)
8.6.1. Therapy Overview
8.6.2. Current Development Status
8.6.3. Key Clinical Trial Results
8.6.4. Dosage Regimen and Manufacturing
8.7. Ciltacabtagene Autoleucel / LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen Biotech)
8.7.1. Therapy Overview
8.7.2. Current Development Status
8.7.3. Key Clinical Trial Results
8.7.4. Dosage Regimen and Manufacturing
8.8. TBI-1501 / CD19 CAR-T Cell Therapy (Takara Bio)
8.8.1. Therapy Overview
8.8.2. Current Development Status
8.8.3. Key Clinical Trial Results
8.8.4. Dosage Regimen and Manufacturing
8.9. Dual Targeting CAR-T Cell therapies (Autolus)
8.9.1. Therapy Overview
8.9.2. Current Development Status
8.9.3. Key Clinical Trial Results
8.9.3.1. AUTO2
8.9.3.2. AUTO3
8.9.3.3. AUTO4
8.9.4. Dosage Regimen and Manufacturing
8.10. CAR-T Cell Therapies (Sinobioway Cell Therapy)
8.10.1. Therapy Overview
8.10.2. Current Development Status
8.10.3. Dosage Regimen and Manufacturing

9. TCR-BASED THERAPY PROFILES
9.1. Chapter Overview
9.2. SPEAR T-Cells (Adaptimmune / GlaxoSmithKline)
9.2.1. Therapy Overview
9.2.1.1. SPEAR T-Cells Technology Platform
9.2.1.2. NY-ESO SPEAR T-Cell
9.2.1.3. Mage-A10 T-Cell Therapy
9.2.1.4. AFP T-Cell Therapy
9.2.1.5. Mage-A4 T-Cell Therapy
9.2.2. Current Development Status
9.2.3. Key Clinical Trial Results
9.2.4. Dosage Regimen and Manufacturing
9.3. IMCgp100 (Immunocore)
9.3.1. Therapy Overview
9.3.2. Current Development Status
9.3.3. Key Clinical Trial Results
9.3.4. Dosage Regimen and Manufacturing
9.4. ALT-801 (Altor BioScience)
9.4.1. Therapy Overview
9.4.2. Current Development Status
9.4.3. Key Clinical Trial Results
9.4.4. Dosage Regimen
9.4.5. Patent Portfolio
9.5. JTCR016 (Juno Therapeutics)
9.5.1. Therapy Overview
9.5.2. Current Development Status
9.5.3. Key Clinical Trial Results
9.5.4. Dosage Regimen and Manufacturing
9.6. CMD-602 / WT1 TCR Therapy (Cell Medica)
9.6.1. Therapy Overview
9.6.1.1. History of Development
9.6.2. Current Development Status
9.6.3. Key Clinical Trial Results
9.6.4. Dosage Regimen and Manufacturing
9.7. TBI-1301 (Takara Bio)
9.7.1. Therapy Overview
9.7.2. Current Development Status
9.7.3. Key Clinical Trial Results
9.7.4. Dosage Regimen and Manufacturing
9.8. MDG1011 (Medigene)
9.8.1. Therapy Overview
9.8.2. Current Development Status
9.8.3. Key Clinical Trial Results
9.8.4. Dosage Regimen and Manufacturing

10. TIL-BASED THERAPY PROFILES
10.1. Chapter Overview
10.2. Autologous TIL Therapies (Iovance Biotherapeutics)
10.2.1. Therapy Overview
10.2.2. Current Development Status
10.2.2.1. LN-144
10.2.2.2. LN-145
10.2.3. Key Clinical Trial Results
10.2.4. Dosage Regimen and Manufacturing
10.2.5. Patent Portfolio
10.3. TIL (Nantes University Hospital)
10.3.1. Therapy Overview
10.3.2. Current Development Status
10.3.3. Key Clinical Trial Results
10.3.4. Dosage Regimen and Manufacturing
10.4. TIL (Netherlands Cancer Institute)
10.4.1. Therapy Overview
10.4.2. Current Development Status
10.4.3. Key Clinical Trial Results
10.4.4. Dosage Regimen and Manufacturing

11. KEY THERAPEUTIC AREAS FOR T-CELL THERAPIES
11.1. Chapter Overview
11.2. Hematological Malignancies
11.2.1. Leukemia and Lymphoma
11.2.1.1. Leukemia: Introduction and Epidemiology
11.2.1.1.1. Acute Myeloid Leukemia (AML)
11.2.1.1.2. Chronic Myeloid Leukemia (CML)
11.2.1.1.3. Acute Lymphocytic Leukemia (ALL)
11.2.1.1.4. Chronic Lymphocytic Leukemia (CLL)
11.2.1.2. Lymphoma: Introduction and Epidemiology
11.2.1.3. Current Treatment Landscape
11.2.1.3.1. Targeted Therapies
11.2.1.4. T-Cell Immunotherapy and Affiliated Research Landscape
11.2.1.4.1. CAR-T Cell Therapies and Leukemia / Lymphoma
11.2.1.4.2. TCR-based Therapies and Leukemia / Lymphoma
11.2.1.4.3. TIL-based Therapies and Leukemia
11.2.2. Multiple Myeloma
11.2.2.1. Introduction and Epidemiology
11.2.2.2. Current Treatment Landscape
11.2.2.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3. Solid Tumors
11.3.1. Metastatic Melanoma
11.3.1.1. Introduction and Epidemiology
11.3.1.2. Current Treatment Landscape
11.3.1.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.1.3.1. CAR-T Cell Therapies and Metastatic Melanoma
11.3.1.3.2. TCR-based Therapies and Metastatic Melanoma
11.3.1.3.3. TIL-based Therapies and Metastatic Melanoma
11.3.2. Lung Cancer
11.3.2.1. Introduction and Epidemiology
11.3.2.2. Current Treatment Landscape
11.3.2.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.3. Pancreatic Cancer
11.3.3.1. Introduction and Epidemiology
11.3.3.2. Current Treatment Landscape
11.3.3.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.3.3.1. CAR-T Cell Therapies and Pancreatic Cancer
11.3.3.3.2. TCR-based Therapies and Pancreatic Cancer
11.3.3.3.3. TIL-based Therapies and Pancreatic Cancer
11.3.4. Liver Cancer
11.3.4.1. Current Treatment Landscape
11.3.4.2. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.4.2.1. CAR-T Cell Therapies and Liver Cancer
11.3.4.2.2. TCR-based Therapies and Liver Cancer
11.3.4.2.3. TIL-based Therapies and Liver Cancer
11.3.5. Breast Cancer
11.3.5.1. Introduction and Epidemiology
11.3.5.2. Current Treatment Landscape
11.3.5.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.5.3.1. CAR-T Cell Therapies and Breast Cancer
11.3.5.3.2. TCR-based Therapies and Breast Cancer
11.3.5.3.3. TIL-based Therapies and Breast Cancer
11.3.6. Ovarian Cancer
11.3.6.1. Introduction and Epidemiology
11.3.6.2. Current Treatment Landscape
11.3.6.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.6.3.1. CAR-T Cell Therapies and Ovarian Cancer
11.3.6.3.2. TCR-based Therapies and Ovarian Cancer
11.3.6.3.3. TIL-based Therapies and Ovarian Cancer
11.3.7. Bladder Cancer
11.3.7.1. Introduction and Epidemiology
11.3.7.2. Current Treatment Landscape
11.3.7.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.8. Kidney Cancer
11.3.8.1. Introduction and Epidemiology
11.3.8.2. Current Treatment Landscape
11.3.8.3. T-Cell Immunotherapy and Affiliated Research Landscape

12. EMERGING TECHNOLOGIES
12.1. Chapter Overview
12.2. Genome Editing Technologies
12.2.1. Technology Overviews
12.2.2. Applications
12.2.3. Emerging Technology Platforms Used in T-Cell Therapies
12.2.3.1. CRISPR / Cas9 System
12.2.3.1.1. Key Components and Function
12.2.3.1.2. Mechanism of Action
12.2.3.1.3. Targeting Efficiency and Challenges
12.2.3.1.4. Next-GEN CRISPR Technology
12.2.3.1.5. Technology Providers
12.2.3.1.5.1. Editas Medicine
12.2.3.1.5.2. Intellia Therapeutics
12.2.3.1.5.3. CRISPR Therapeutics
12.2.3.1.5.4. Beam Therapeutics
12.2.3.1.5.5. Gracell Biotechnologies
12.2.3.2. TALENs
12.2.3.2.1. Key Components and Function
12.2.3.2.2. Mechanism of Action
12.2.3.2.3. Advantages and Challenges
12.2.3.2.4. Technology Providers
12.2.3.2.4.1. Cellectis
12.2.3.2.4.2. Editas Medicine
12.2.3.3. megaTAL
12.2.3.3.1. Technology Providers
12.2.3.3.1.1. bluebird bio
12.2.3.4. Zinc Finger Nuclease
12.2.3.4.1. Technology Providers
12.2.3.4.1.1. Sangamo Therapeutics
12.2.4. Competitive Analysis: Gene Editing Platforms
12.3. Designing T-Cell Therapies with Improved Characteristics
12.3.1. Technologies for Targeting Multiple Cancers
12.3.1.1. Antibody Coupled T-Cell Receptor
12.3.1.1.1. Unum Therapeutics
12.3.1.2. NKR-T Platform
12.3.1.2.1. Celyad
12.3.1.2.2. Glycostem
12.3.2. Technologies for Improved Safety
12.3.2.1. Armored CAR and EGFRt Technology
12.3.2.1.1. Juno Therapeutics
12.3.2.2. RheoSwitch Therapeutic System
12.3.2.2.1. Intrexon
12.3.2.1. Inducible Caspase 9 Safety Switch
12.3.2.1.1. Bellicum Pharmaceuticals
12.3.2.1.1.1. CaspaCIDe Technology
12.3.2.1.1.2. CIDeCAR Technology
12.3.2.1.1.3. GoCAR-T Technology
12.3.2.2. On-Off Switch, Multiple Companies
12.3.2.2.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
12.3.2.2.2. On-Off Switch (Theravectys)
12.3.2.3. Other Technologies to Improve CAR-T Safety
12.3.3. Allogeneic Technologies
12.3.3.1. CIK CAR-T Cells (Formula Pharmaceuticals)
12.3.3.2. Allogeneic Platform (Celyad)
12.3.3.3. Allogeneic Platform (Cellectis)

13. PARTNERSHIPS AND COLLABORATIONS
13.1. Chapter Overview
13.2. Partnership Models
13.3. T-Cell Immunotherapies Market: Partnerships and Collaborations
13.3.1. Analysis by Year of Partnerships
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Type of Partnership and Type of Product
13.3.4. Analysis by Type of Industry and Type of Product
13.3.5. Analysis by Individual Products
13.3.6. Most Active Industry Players: Analysis by Number of Partnerships
13.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
13.3.8. Most Active Contract Manufacturers: Analysis by Number of Manufacturing Agreements
13.3.9. Regional Analysis
13.3.10. Intercontinental and Intracontinental Agreements

14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. T-Cell Immunotherapy Market: Funding and Investment Analysis
14.3.1. Analysis by Number of Funding Instances
14.3.2. Analysis by Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis by Amount Invested across Different Types of Therapies
14.3.5. Most Active Players: Analysis by Number of Instances
14.3.6. Analysis by Amount Invested by Different Type of Investors
14.3.7. Most Active Investors: Analysis by Number of Instances
14.3.8. Regional Analysis by Amount Invested

15. OTHER T-CELL IMMUNOTHERAPIES
15.1. Chapter Overview
15.2. Other T-Cell Immunotherapies
15.2.1. Analysis by Phase of Development
15.2.2. Analysis by Target Therapeutic Area
15.2.3. Analysis by Types of Cells
15.2.4. Analysis by Source of T-Cells
15.3. Treg Cell Therapy
15.3.1. Caladrius Biosciences
15.3.2. TRACT Therapeutics
15.3.3. Cellenkos
15.3.4. Other Companies
15.4. T-Cell-based Vaccines
15.4.1. Immunovative Therapies
15.4.2. TVAX Biomedical
15.5. Virus-Driven T-Cell Therapy
15.5.1. Atara Biotherapeutics
15.5.2. bluebird bio
15.5.3. Cell Medica
15.5.4. Eutilex
15.5.5. Tessa Therapeutics
15.5.6. ViGenCell
15.6. Fucosylated T-Cell Therapy
15.6.1. Targazyme
15.7. PD-1 Knockout Engineered T-Cell Therapy
15.7.1. Chengdu MedGenCell
15.7.2. Anhui Kedgene Biotechnology
15.8. TAC-T Cell Therapy
15.8.1. Triumvira Immunologics
15.9. Gama Delta T-Cell Therapy
15.9.1. GammaCell Bio-Technologies
15.9.2. TC Biopharm

16. CASE STUDY: CELL THERAPY MANUFACTURING
16.1. Chapter Overview
16.2. Overview of Cell Therapy Manufacturing
16.3. Cell Therapy Manufacturing Models
16.3.1. Centralized Manufacturing Model
16.3.2. Decentralized Manufacturing Model
16.4. Scalability of Cell Therapy Manufacturing Processes
16.4.1. Scale-Up
16.4.2. Scale-Out
16.5. Types of Cell Therapy Manufacturers
16.6. Key Challenges Related to Manufacturing Cell Therapies
16.7. Important Factors for Cell Therapy Manufacturing
16.7.1. Characterization
16.7.2. Cost of Goods
16.8. Automation of Cell Therapy Manufacturing Processes
16.9. Cell Therapy Manufacturing Supply Chain
16.10. Companies with In-House Capabilities
16.11. Contract Manufacturers
16.12. Regulatory Landscape

17. COST PRICE ANALYSIS
17.1. Chapter Overview
17.2. Factors Contributing to the High Price of Cell / Gene Therapies
17.3. Pricing Models for T-Cell Immunotherapies
17.3.1. Based on Associated Costs
17.3.2. Based on Availability of Competing Products
17.3.3. Based on Patient Segment
17.3.4. Based on the Opinions of Industry Experts
17.4. Reimbursement-related Considerations For T-Cell Immunotherapies
17.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies

18. MARKET SIZING AND OPPORTUNITY ANALYSIS
18.1. Chapter Overview
18.2. Scope and Limitations
18.3. Key Assumptions and Forecast Methodology
18.4. Overall T-Cell Immunotherapy Market, 2019-2030
18.4.1. T-Cell Immunotherapy Market: Distribution by Type of Therapy
18.4.2. T-Cell Immunotherapy Market: Distribution by Target Indications
18.4.3. T-Cell Immunotherapy Market: Distribution by Target Antigen
18.4.4. T-Cell Immunotherapy Market: Distribution by Key Players
18.4.5. T-Cell Immunotherapy Market: Distribution by Geography
18.5. T-Cell Immunotherapy Market: Value Creation Analysis
18.6. Overall CAR-T Cell Therapies Market, 2019-2030
18.6.1. CAR-T Cell Therapies Market: Distribution by Target Indication
18.6.2. CAR-T Cell Therapies Market: Distribution by Target Antigen
18.6.3. CAR-T Cell Therapies Market: Distribution by Key Players
18.6.4. CAR-T Cell Therapies Market: Distribution by Geography
18.6.5. Product Wise Sales Forecasts
18.6.5.1. KYMRIAH® (Novartis)
18.6.5.1.1. Target Patient Population
18.6.5.1.2. Sales Forecast
18.6.5.1.3. Net Present Value
18.6.5.1.4. Value Creation Analysis
18.6.5.2. YESCARTA® (Gilead Sciences)
18.6.5.2.1. Target Patient Population
18.6.5.2.2. Sales Forecast
18.6.5.2.3. Net Present Value
18.6.5.2.4. Value Creation Analysis
18.6.5.3. Tecartus® / Brexucabtagene Autoleucel (Gilead Sciences)
18.6.5.3.1. Target Patient Population
18.6.5.3.2. Sales Forecast
18.6.5.3.3. Net Present Value
18.6.5.3.4. Value Creation Analysis
18.6.5.4. Idecabtagene Vicleucel / bb2121 (bluebird bio / Celgene)
18.6.5.4.1. Target Patient Population
18.6.5.4.2. Sales Forecast
18.6.5.4.3. Net Present Value
18.6.5.4.4. Value Creation Analysis
18.6.5.5. Ciltacabtagene Autoleucel / LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen)
18.6.5.5.1. Target Patient Population
18.6.5.5.2. Sales Forecast
18.6.5.5.3. Net Present Value
18.6.5.5.4. Value Creation Analysis
18.6.5.6. JCAR017 (Juno Therapeutics / Celgene / Wuxi AppTec)
18.6.5.6.1. Target Patient Population
18.6.5.6.2. Sales Forecast
18.6.5.6.3. Net Present Value
18.6.5.6.4. Value Creation Analysis
18.6.5.7. MB-CART19.1 (Miltenyi Biotec)
18.6.5.7.1. Target Patient Population
18.6.5.7.2. Sales Forecast
18.6.5.7.3. Net Present Value
18.6.5.7.4. Value Creation Analysis
18.6.5.8. Descartes-11 (Cartesian Therapeutics)
18.6.5.8.1. Target Patient Population
18.6.5.8.2. Sales Forecast
18.6.5.8.3. Net Present Value
18.6.5.8.4. Value Creation Analysis
18.6.5.9. MB-102 (Mustang Bio)
18.6.5.9.1. Target Patient Population
18.6.5.9.2. Sales Forecast
18.6.5.9.3. Net Present Value
18.6.5.9.4. Value Creation Analysis
18.6.5.10. huCART19 / CTL119 (Novartis)
18.6.5.10.1. Target Patient Population
18.6.5.10.2. Sales Forecast
18.6.5.10.3. Net Present Value
18.6.5.10.4. Value Creation Analysis
18.6.5.11. CD19 CAR-T (Sinobioway Cell Therapy)
18.6.5.11.1. Target Patient Population
18.6.5.11.2. Sales Forecast
18.6.5.11.3. Net Present Value
18.6.5.11.4. Value Creation Analysis
18.6.5.12. AUTO1 (Autolus)
18.6.5.12.1. Target Patient Population
18.6.5.12.2. Sales Forecast
18.6.5.12.3. Net Present Value
18.6.5.12.4. Value Creation Analysis
18.6.5.13. AUTO3 (Autolus)
18.6.5.13.1. Target Patient Population
18.6.5.13.2. Sales Forecast
18.6.5.13.3. Net Present Value
18.6.5.13.4. Value Creation Analysis
18.6.5.14. AUTO4 (Autolus)
18.6.5.14.1. Target Patient Population
18.6.5.14.2. Sales Forecast
18.6.5.14.3. Net Present Value
18.6.5.14.4. Value Creation Analysis
18.6.5.15. GPC3 CAR-T (Shanghai GeneChem)
18.6.5.15.1. Target Patient Population
18.6.5.15.2. Sales Forecast
18.6.5.15.3. Net Present Value
18.6.5.15.4. Value Creation Analysis
18.6.5.16. BCMA CAR-T (The Pregene ShenZhen Biotechnology)
18.6.5.16.1. Target Patient Population
18.6.5.16.2. Sales Forecast
18.6.5.16.3. Net Present Value
18.6.5.16.4. Value Creation Analysis
18.6.5.17. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology)
18.6.5.17.1. Target Patient Population
18.6.5.17.2. Sales Forecast
18.6.5.17.3. Net Present Value
18.6.5.17.4. Value Creation Analysis
18.6.5.18. CD19 CAR-T (Shanghai Bioray Laboratory)
18.6.5.18.1. Target Patient Population
18.6.5.18.2. Sales Forecast
18.6.5.18.3. Net Present Value
18.6.5.18.4. Value Creation Analysis
18.6.5.19. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
18.6.5.19.1. Target Patient Population
18.6.5.19.2. Sales Forecast
18.6.5.19.3. Net Present Value
18.6.5.19.4. Value Creation Analysis
18.6.5.20. PCAR-019 (PersonGen BioTherapeutics)
18.6.5.20.1. Target Patient Population
18.6.5.20.2. Sales Forecast
18.6.5.20.3. Net Present Value
18.6.5.20.4. Value Creation Analysis
18.6.5.21. TBI-1501 (Takara Bio)
18.6.5.21.1. Target Patient Population
18.6.5.21.2. Sales Forecast
18.6.5.21.3. Net Present Value
18.6.5.21.4. Value Creation Analysis
18.6.5.22. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
18.6.5.22.1. Target Population
18.6.5.22.2. Sales Forecast
18.6.5.22.3. Net Present Value
18.6.5.22.4. Value Creation Analysis
18.6.5.23. CCT301 CAR-T Cell Therapy (Shanghai Sinobioway Sunterra Biotech)
18.6.5.23.1. Target Patient Population
18.6.5.23.2. Sales Forecast
18.6.5.23.3. Net Present Value
18.6.5.23.4. Value Creation Analysis
18.6.5.24. BinD19 (Shenzhen BinDeBio)
18.6.5.24.1. Target Patient Population
18.6.5.24.2. Sales Forecast
18.6.5.24.3. Net Present Value
18.6.5.24.4. Value Creation Analysis
18.6.5.25. CARCIK-CD19 (Formula Pharmaceuticals)
18.6.5.25.1. Target Patient Population
18.6.5.25.2. Sales Forecast
18.6.5.25.3. Net Present Value
18.6.5.25.4. Value Creation Analysis
18.6.5.26. EGFR CART Cell Therapy (The Beijing Pregene Science and Technology)
18.6.5.26.1. Target Patient Population
18.6.5.26.2. Sales Forecast
18.6.5.26.3. Net Present Value
18.6.5.26.4. Value Creation Analysis
18.6.5.27. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology)
18.6.5.27.1. Target Patient Population
18.6.5.27.2. Sales Forecast
18.6.5.27.3. Net Present Value
18.6.5.27.4. Value Creation Analysis
18.6.5.28. PBCAR269A (Precision BioSciences)
18.6.5.28.1. Target Patient Population
18.6.5.28.2. Sales Forecast
18.6.5.28.3. Net Present Value
18.6.5.28.4. Value Creation Analysis
18.6.5.29. CD123 CAR-T cells (Chongqing Precision Biotech)
18.6.5.29.1. Target Patient Population
18.6.5.29.2. Sales Forecast
18.6.5.29.3. Net Present Value
18.6.5.29.4. Value Creation Analysis
18.6.5.30. BCMA CAR-T (Chongqing Precision Biotech)
18.6.5.30.1. Target Patient Population
18.6.5.30.2. Sales Forecast
18.6.5.30.3. Net Present Value
18.6.5.30.4. Value Creation Analysis
18.6.5.31. CEA CAR-T cells (Chongqing Precision Biotech)
18.6.5.31.1. Target Patient Population
18.6.5.31.2. Sales Forecast
18.6.5.31.3. Net Present Value
18.6.5.31.4. Value Creation Analysis
18.6.5.32. iC9-CAR19 T cells (Bellicum Pharmaceuticals)
18.6.5.32.1. Target Patient Population
18.6.5.32.2. Sales Forecast
18.6.5.32.3. Net Present Value
18.6.5.32.4. Value Creation Analysis
18.6.5.33. P-BCMA-101 (Poseida Therapeutics)
18.6.5.33.1. Target Patient Population
18.6.5.33.2. Sales Forecast
18.6.5.33.3. Net Present Value
18.6.5.33.4. Value Creation Analysis
18.6.5.34. CD19 CAR-T (iCarTAB BioMed)
18.6.5.34.1. Target Patient Population
18.6.5.34.2. Sales Forecast
18.6.5.34.3. Net Present Value
18.6.5.34.4. Value Creation Analysis
18.6.5.35. CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
18.6.5.35.1. Target Patient Population
18.6.5.35.2. Sales Forecast
18.6.5.35.3. Net Present Value
18.6.5.35.4. Value Creation Analysis
18.6.5.36. BPX-601 (Bellicum Pharmaceuticals)
18.6.5.36.1. Target Patient Population
18.6.5.36.2. Sales Forecast
18.6.5.36.3. Net Present Value
18.6.5.36.4. Value Creation Analysis
18.6.5.37. MUC1 CAR-T (PersonGen BioTherapeutics (Suzhou))
18.6.5.37.1. Target Patient Population
18.6.5.37.2. Sales Forecast
18.6.5.37.3. Net Present Value
18.6.5.37.4. Value Creation Analysis
18.7. Overall TCR-based Therapies Market
18.7.1. TCR-Based Therapies Market: Distribution by Target Indication
18.7.2. TCR-Based Therapies Market: Distribution by Target Antigen
18.7.3. TCR-Based Therapies Market: Distribution by Key Players
18.7.4. TCR-Based Therapies Market: Distribution by Geography
18.7.5. Product Wise Sales Forecasts
18.7.5.1. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck)
18.7.5.1.1. Target Patient Population
18.7.5.1.2. Sales Forecast
18.7.5.1.3. Net Present Value
18.7.5.1.4. Value Creation Analysis
18.7.5.2. IMCgp100 (Immunocore)
18.7.5.2.1. Target Patient Population
18.7.5.2.2. Sales Forecast
18.7.5.2.3. Net Present Value
18.7.5.2.4. Value Creation Analysis
18.7.5.3. ADP-A2M4 (Adaptimmune Therapeutics)
18.7.5.3.1. Target Patient Population
18.7.5.3.2. Sales Forecast
18.7.5.3.3. Net Present Value
18.7.5.3.4. Value Creation Analysis
18.7.5.4. TBI-1301 (Takara Bio)
18.7.5.4.1. Target Patient Population
18.7.5.4.2. Sales Forecast
18.7.5.4.3. Net Present Value
18.7.5.4.4. Value Creation Analysis
18.7.5.5. ALT 801 (Altor BioScience)
18.7.5.5.1. Target Patient Population
18.7.5.5.2. Sales Forecast
18.7.5.5.3. Net Present Value
18.7.5.5.4. Value Creation Analysis
18.7.5.6. JTCR016 (Juno Therapeutics)
18.7.5.6.1. Target Patient Population
18.7.5.6.2. Sales Forecast
18.7.5.6.3. Net Present Value
18.7.5.6.4. Value Creation Analysis
18.7.5.7. LioCyx (Lion TCR)
18.7.5.7.1. Target Patient Population
18.7.5.7.2. Sales Forecast
18.7.5.7.3. Net Present Value
18.7.5.7.4. Value Creation Analysis
18.7.5.8. YT-E001 (China Immunotech)
18.7.5.8.1. Target Patient Population
18.7.5.8.2. Sales Forecast
18.7.5.8.3. Net Present Value
18.7.5.8.4. Value Creation Analysis
18.7.5.9. MDG1011 (Medigene)
18.7.5.9.1. Target Patient Population
18.7.5.9.2. Sales Forecast
18.7.5.9.3. Net Present Value
18.7.5.9.4. Value Creation Analysis
18.7.5.10. TC-110 (TCR2 Therapeutics)
18.7.5.10.1. Target Patient Population
18.7.5.10.2. Sales Forecast
18.7.5.10.3. Net Present Value
18.7.5.10.4. Value Creation Analysis
18.7.5.11. LMBP2-specific TCR-T (TCR CURE Biopharma Technology)
18.7.5.11.1. Target Patient Population
18.7.5.11.2. Sales Forecast
18.7.5.11.3. Net Present Value
18.7.5.11.4. Value Creation Analysis
18.8. Overall TIL-Based Therapies Market
18.8.1. TIL-Based Therapies Market: Distribution by Target Indication
18.8.2. TIL-Based Therapies Market: Distribution by Key Players
18.8.3. TIL-Based Therapies Market: Distribution by Geography
18.8.4. Product Wise Sales Forecasts
18.8.4.1. TILs (Nantes University Hospital)
18.8.4.1.1. Target Patient Population
18.8.4.1.2. Sales Forecast
18.8.4.1.3. Net Present Value
18.8.4.1.4. Value Creation Analysis
18.8.4.2. TILs (Netherlands Cancer Institute)
18.8.4.2.1. Target Patient Population
18.8.4.2.2. Sales Forecast
18.8.4.2.3. Net Present Value
18.8.4.2.4. Value Creation Analysis
18.8.4.3. Lifileucel (LN-144) (Iovance Biotherapeutics)
18.8.4.3.1. Target Patient Population
18.8.4.3.2. Sales Forecast
18.8.4.3.3. Net Present Value
18.8.4.3.4. Value Creation Analysis
18.8.4.4. LN-145 (Iovance Biotherapeutics)
18.8.4.4.1. Target Patient Population
18.8.4.4.2. Sales Forecast
18.8.4.4.3. Net Present Value
18.8.4.4.4. Value Creation Analysis
18.8.4.5. LTX-315 and TILs (Lytix Biopharma)
18.8.4.5.1. Target Patient Population
18.8.4.5.2. Sales Forecast
18.8.4.5.3. Net Present Value
18.8.4.5.4. Value Creation Analysis
18.8.4.6 IOV-2001 (Iovance Biotherapeutics)
18.8.4.6.1. Target Patient Population
18.8.4.6.2. Sales Forecast
18.8.4.6.3. Net Present Value
18.8.4.6.4. Value Creation Analysis
18.8.4.7. Allogeneic Donor Lymphocytes (Amgen)
18.8.4.7.1. Target Patient Population
18.8.4.7.2. Sales Forecast
18.8.4.7.3. Net Present Value
18.8.4.7.4. Value Creation Analysis
18.8.4.8. Donor Lymphocyte Infusion (Incyte)
18.8.4.8.1. Target Patient Population
18.8.4.8.2. Sales Forecast
18.8.4.8.3. Net Present Value
18.8.4.8.4. Value Creation Analysis
18.8.4.9. TILs (Bristol-Myers Squibb)
18.8.4.9.1. Target Patient Population
18.8.4.9.2. Sales Forecast
18.8.4.9.3. Net Present Value
18.8.4.9.4. Value Creation Analysis
18.8.4.10. UTIL-01 and CoTIL-01 (Immetacyte)
18.8.4.10.1. Target Patient Population
18.8.4.10.2. Sales Forecast
18.8.4.10.3. Net Present Value
18.8.4.10.4. Value Creation Analysis
18.8.4.11. TILs (Intima Bioscience)
18.8.4.11.1. Target Patient Population
18.8.4.11.2. Sales Forecast
18.8.4.11.3. Net Present Value
18.8.4.11.4. Value Creation Analysis
18.8.4.12. TILs (CAR-T (Shanghai) Cell Biotechnology)
18.8.4.12.1. Target Patient Population
18.8.4.12.2. Sales Forecast (USD Million)
18.8.4.12.3. Net Present Value (USD Million)
18.8.4.12.4. Value Creation Analysis

19. PROMOTIONAL ANALYSIS
19.1. Chapter Overview
19.2. Channels used for Promotional Campaigns
19.3. Summary of Product Website Analysis
19.4. Summary of Patient Support Services and Informative Downloads
19.5. KYMRIAH®: Promotional Analysis
19.5.1. Drug Overview
19.5.2. Product Website Analysis
19.5.2.1. Messages for Healthcare Professionals
19.5.2.2. Messages for Patients
19.5.3. Patient Support Services and Informative Downloads
19.5.4. Other Promotional Activities
19.5.4.1. Presence in Conferences
19.6. YESCARTA®: Promotional Analysis
19.6.1. Drug Overview
19.6.2. Product Website Analysis
19.6.2.1. Messages for Healthcare Professionals
19.6.2.2. Messages for Patients
19.6.3. Patient Support Services and Informative Downloads
19.6.4. Other Promotional Activities
19.6.4.1. Presence in Conferences

20. COMPANY PROFILES
20.1. Chapter Overview
20.2. Adaptimmune Therapeutics
20.3. Autolus
20.4. bluebird bio
20.5. CARsgen Therapeutics
20.6. Celgene
20.7. Cell Medica
20.8. Cellectis
20.9. Cellular Biomedicine Group
20.10. Immunocore
20.11. Innovative Cellular Therapeutics
20.12. Iovance Biotherapeutics
20.13. Kite Pharma
20.14. Lion TCR
20.15. Noile-Immune Biotech
20.16. Novartis
20.17. Shanghai GeneChem
20.18. Sinobioway Cell Therapy
20.19. Takara Bio
20.20. Unum Therapeutics
20.21. ZIOPHARM Oncology

21. CONCLUDING REMARKS
21.1. Chapter Overview
21.2. Key Takeaways

22. EXECUTIVE INSIGHTS
22.1. Chapter Overview
22.2. Cell Therapies
22.2.1 Interview Transcript: Tim Oldham, Chief Executive Officer 
22.3. Glycostem Therapeutics
22.3.1 Interview Transcript: Troels Jordansen, Chief Executive Officer
22.4. Gracell Biotechnologies
22.4.1 Interview Transcript: Wei (William) Cao, Chief Executive Officer
22.5. Lion TCR
22.5.1 Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
22.6. TxCell
22.6.1 Interview Transcript: Miguel Forte, Chief Operating Officer
22.7. Kite Pharma
22.7.1 Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
22.8. Celyad
22.8.1 Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncologys 
22.9. Iovance Biotherapeutics
22.9.1 Interview Transcript: Peter Ho, Director, Process Development
22.10. Waisman Biomanufacturing
22.10.1 Interview Transcript: Brian Dattilo, Manager of Business Development
22.11. Theravectys
22.11.1 Interview Transcript: Aino Kalervo, Competitive Intelligence Manager, Strategy & Business Development
22.12. Changhai Hospital
22.12.1 Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology
22.13. University of Colorado
22.13.1 Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

Note: Product cover images may vary from those shown
3 of 4
  • 5AM Ventures
  • 6 Dimensions Capital
  • AbbVie Ventures
  • AbCheck
  • AbClon
  • Abingworth
  • AbVitro
  • Aditya Birla Capital
  • ACEA Biosciences
  • Acorn Pacific Ventures
  • Adage Capital Management
  • Adaptimmune Therapeutics    
  • Adicet Bio
  • Adimab
  • Aeon Therapeutics
  • AffyImmune Therapeutics
  • AFG private Equity
  • Agent Capital
  • AgenTus Therapeutics
  • Agreen Biotech 
  • Aisling Capital 
  • Aju IB
  • AJU IB INVESTMENT
  • AK (Suzhou) Biomedical
  • Alexandria Venture Investments
  • Allife Medical Science and Technology
  • Allogene Therapeutics
  • Alpine Immune Sciences
  • Alta Partners
  • Altor Bioscience
  • Alumni Ventures Group (AVG)
  • Amgen
  • Amgen Ventures
  • Andera Partners
  • Andreessen Horowitz
  • ANTAGENE
  • Aquilo Capital Management 
  • Arbele
  • Arcellx
  • ARCH Venture Partners
  • Arix Bioscience
  • ArrowMark Partners
  • A*STAR Research
  • Astellas Pharma
  • Astellas Venture Management
  • Asymptote 
  • AT Impf
  • Atara Biotherapeutics
  • Atlas Venture
  • Atossa Therapeutics
  • Atreca 
  • Aurora Biopharma
  • Autolus
  • Avacta
  • Avalon GloboCare
  • Avoro Capital Advisors
  • AVIC International Holding
  • Baader Bank
  • Baillie Gifford
  • BankInvest Biomedical Venture
  • Baxalta
  • Baxalta Ventures
  • Baxter Ventures
  • Baylor College of Medicine
  • Be The Match BioTherapies
  • Beam Therapeutics
  • Beijing Biohealthcare Biotechnology
  • Beijing Doing Biomedical Technology
  • Beijing Immunochina Medical Science & Technology 
  • Beijing Mabworks Biotech
  • Beijing Mario Biotech
  • Beijing Sanwater Biological Technology
  • Belgian Public Health Insurer
  • Bellco Capital
  • Bellicum Pharmaceuticals
  • Bessemer Venture Partners
  • Bezos Expeditions
  • Bill & Melinda Gates Foundation 
  • BioAtla
  • Bioceltech Therapeutics
  • Bio-Gene Technology
  • Biomedical Catalyst 
  • BioNTech
  • Biosceptre
  • bluebird bio
  • BNH Investment
  • Boehringer Ingelheim 
  • Boxer Capital 
  • Boya Jiyin
  • Bpifrance
  • Brace Pharma Capital
  • BrightEdge 
  • Bristol Myers Squibb
  • Broadfin Capital
  • BVCF Management
  • Cabaret Biotech
  • Caladrius Biosciences
  • California Institute for Regenerative Medicine (CIRM) 
  • Canaan Partners
  • Cancer Prevention and Research Institute of Texas 
  • Captain T Cell
  • Caribou Biosciences
  • Carina Biotech
  • CARsgen Therapeutics
  • CAR-T (Shanghai) Biotechnology
  • Cartesian Therapeutics
  • Cartherics
  • Casdin Capital
  • Casebia Therapeutics
  • Celgene
  • Cell and Gene Therapy Catapult
  • Cell Design Labs
  • Cellectis
  • CELLforCURE
  • Cellular Biomedicine Group 
  • Cellular Therapeutics
  • Celyad 
  • Chengdu Miaoji Medical Technology
  • Children’s Hospital of Philadelphia
  • China (Nanjing) Cell Valley 
  • China Immunotech (Beijing) Biotechnology
  • China Regenerative Medicine International (CRMI)
  • Chongqing Precision Biotech
  • Clough Capital Partners
  • Cognate BioServices
  • Cormorant Asset Management
  • Cowen Healthcare Investments
  • CRISPR Therapeutics
  • Cryoport
  • CTI Clinical Trial and Consulting Services
  • CTM CRC
  • Curative Ventures
  • CureSearch
  • CytoLumina Technologies
  • CytoMed Therapeutics
  • Cytovant Sciences
  • Deerfield Management
  • Delenex Therapeutics  
  • dievini Hopp Biotech
  • Direct Selling Association of Malaysia (DSAM)
  • Ditch Plains Capital Management
  • DS Asset Management
  • Duke Management Company
  • EcoR1 Capital
  • EDBI
  • Editas Medicine 
  • Edmond de Rothschild Venture Capital
  • Efung Capital
  • Eli Lilly
  • Endocyte
  • The Energy and Resources Institute
  • Eureka Therapeutics
  • European Commission
  • European Innovation Council (EIC) 
  • European Investment Bank
  • Eutilex
  • EXUMA Biotech
  • F1 BioVentures
  • F2 Ventures
  • Fate Therapeutics
  • FetoLumina Technologies 
  • Federal Ministry of Education and Research (BMBF)
  • Fidelity Biosciences
  • Fidelity Management and Research
  • Finnish Funding Agency for Technology and Innovation
  • Five Prime Therapeutics
  • Five Rings Capital
  • Flagship Pioneering
  • Flagship Ventures
  • Fondazione Matilde Tettamanti Menotti De Marchi Onlus
  • Foresite Capital
  • Forevertek Biotechnology
  • Formula Pharmaceuticals
  • Fosun Pharmaceutical
  • Fotress Biotech
  • F-Prime
  • Franklin Templeton Investments
  • Friedreich’s Ataxia Research Alliance (FARA)
  • Fundamenta Therapeutics
  • G.N. Tech Venture
  • Gadeta
  • GC LabCell
  • GC Pharma
  • GE Global Research
  • GE Healthcare Life Sciences 
  • Genentech
  • Genmab
  • Genus Oncology
  • GigaGen
  • Gilead Sciences
  • GlaxoSmithKline
  • Glycostem 
  • GlyTherix
  • Google Ventures
  • GP Capital
  • Gracell Biotechnologies
  • Grower Venture Capital
  • Guangdong Chongye Holdings
  • Guangdong Xiangxue Precision Medical Technology
  • Guangdong Zhaotai InVivo Biomedicine
  • Guangzhou Anjie Biomedical Technology
  • Guangzhou FineImmune Biotechnology
  • Guangzhou Yi yang Biological Technology
  • GV
  • Haitong International Securities Group
  • Hebei Senlang Biotechnology
  • Helix BioPharma
  • Henan Hualong Biotechnology 
  • Hengzhen Biotechnology
  • Hillhouse Capital Group
  • Hopp Biotech holding
  • Horizon Discovery
  • Horizon Technology Finance
  • Hrain Biotechnology
  • HuaDao (Shanghai) Biomedical
  • Hudson Bay Capital Management 
  • Hunan Yongren Medical Innovation 
  • Hunan Zhaotai Yongren Biotech
  • Hunan Zhaotai Yongren Medical Innovation
  • iCAR Bio Therapeutics 
  • iCarTAB BioMed
  • iCell Gene Therapeutics
  • Icell Kealex Therapeutics
  • ICON
  • Immatics
  • Immetacyte
  • Immune Therapeutics
  • Immunocore
  • Imperial Innovations
  • Innovate UK
  • Innovative Cellular Therapeutics
  • Intellia Therapeutics
  • Intima Bioscience
  • Invectys
  • Invesco Perpetual
  • Investing Women
  • Iovance Biotherapeutics
  • IRICoR
  • Janssen
  • Janus Capital Group
  • Janus Henderson Investors
  • Japan Science and Technology Agency (JST)
  • Jebsen Capital
  • Jianxin Capital
  • JIC GenesisFountain Healthcare Ventures
  • Jichi Medical University
  • Johnson & Johnson Innovation
  • Jolly Innovation Ventures
  • Junchenda Capital
  • Juno Therapeutics
  • Juventas Cell Therapy
  • JVC Investment Partners
  • JW Biotechnology
  • JW Therapeutics
  • KAEDI
  • Kaitai Capital
  • Karolinska Institute
  • Karst Peak Capital
  • Kecellitics Biotech
  • Key Biologics
  • Khosla Ventures
  • King Star Capital
  • Kington Capital
  • Kite Pharma
  • Kleiner Perkins
  • Kolon Investment
  • Kuur Therapeutics
  • KSQ Therapeutics
  • KTB Ventures
  • Laurion Capital Management
  • Legend Biotech
  • Legend Capital 
  • Leiden University Medical Center
  • Leucid Bio
  • Level One Partners
  • LG Technology Ventures
  • LH Ventures
  • Life Technologies
  • Lifeline Ventures
  • Lightstone Ventures
  • Lilly Asia Ventures
  • Liminatus Pharma
  • Lion TCR 
  • Living Pharma
  • Longitude Capital
  • Lonza
  • Lonza Biologics
  • Loyal Valley Capital
  • Lucion Group
  • LUMICKS
  • Lupus Ventures
  • Lyell Immunopharma
  • Lytix Biopharma
  • MabQuest 
  • MabVax Therapeutics Holdings
  • Malin
  • Marino Biotechnology
  • Marker Therapeutics
  • MaSTherCell
  • Matrix Capital Management
  • MaxCyte
  • Maxim Group
  • MD Anderson Cancer Center 
  • Medicxi Ventures
  • Medigene 
  • MedImmune
  • Medisix Therapeutics 
  • Medivate Partners
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Merck Serono
  • Merlin Nexus
  • Mesoblast
  • Miller Value Partners
  • Miltenyi Biotec
  • Minerva Biotechnologies
  • MingJu Therapeutics
  • Mirae Asset Capital
  • Mirae Asset Venture Investment
  • Mirae Asset Financial Group
  • Mission Bay Capital
  • MIT Zuid 
  • MolMed
  • MPM Capital
  • MSD Partners
  • Mustang Bio
  • NantKwest
  • NantWorks
  • National Cancer Institute
  • National Institute of Allergy and Infectious Diseases 
  • National Institutes of Health
  • NCL Innovation
  • New Enterprise Associates
  • New Leaf Venture Partners
  • Nextech Invest
  • NIH Small Business Innovation Research (SBIR) 
  • NIPRO
  • Nohla Therapeutics
  • Noile-Immune Biotech
  • Norwegian Research Council (NRC) 
  • Notch Therapeutics
  • Novartis
  • Novartis Institutes for BioMedical Research (NIBR)
  • Novo Nordisk
  • Novo Holdings
  • NSR Financial
  • Oaktree Capital Management
  • Obsidian Therapeutics
  • Oberland Capital Healthcare
  • OCV Partners
  • ODYSSEE Venture
  • Omega Fund 
  • Oncodesign Biotechnology
  • Oncora Medical
  • OncoTracker
  • Oncyte
  • ONO pharmaceutical
  • Opus Bio 
  • OrbiMed Advisors
  • Osage University Partners
  • Oxford Biomedical Research
  • Oxford MEStar 
  • PACT Pharma
  • Panacea Venture
  • Parker Institute for Cancer Immunotherapy
  • Partners Innovation Management
  • Penn Medicine
  • Pentwater Capital Management
  • PeproMene Bio
  • Perceptive Advisors
  • Perceptive Bioscience Investments
  • PersonGen BioTherapeutics (Suzhou)
  • Perspective Advisors
  • Pfenex
  • Pfizer
  • PharmaCell
  • Phio Pharmaceuticals
  • Ping An Ventures
  • Pinze Lifetechnology
  • Pitango Venture Capital
  • Platinum Asset Management
  • Polaris Partners
  • PolyBioCept
  • Pontifax
  • Pontifax AgTech
  • POSCO Capital
  • Poseida Therapeutics
  • Precigen
  • Precision BioSciences
  • Progenitor Cell Therapy
  • ProMAB Biotechnologies
  • Prometheus Laboratories
  • Protheragen
  • PureTech Health
  • Qian Hai Wan Hui Equity Investment Fund Management (Shenzhen)
  • Quan Capital
  • Quogue Capital
  • QVT Financial
  • RA Capital Management
  • Redmile Group
  • RedoxTherapies
  • Regeneron 
  • Remeditex Ventures
  • resTORbio
  • Ridgeback Capital Management
  • Roche
  • Rock Spring Capital
  • Rockland Immunochemicals
  • RTW Investments
  • S.R. One
  • Sabby Management
  • Samsara BioCapital
  • Sangamo Therapeutics
  • Sanofi Ventures
  • Schonfeld Strategic Advisors
  • Scotia Biologics
  • Scottish Enterprise
  • Scottish Investment Bank (SIB)
  • Seattle Genetics
  • Sectoral Asset management
  • Sensei Biotherapeutics
  • Sequoia Capital China
  • Servier
  • Shandong Boyuan Pharmaceutical
  • Shanghai Biomed-Union Biotechnology
  • Shanghai Bioray Laboratory
  • Shanghai Longyao Biotechnology 
  • Shanghai PerHum Therapeutics
  • Shanghai Pudong Innovation Technology Investment
  • Shanghai Sinobioway Sunterra Biotech
  • Shanghai Unicar-Therapy Bio medicine Technology
  • Sheba Medical Center 
  • Shenzen Venture Capital
  • Shenzhen BinDeBio
  • Sherpa Venture Capital
  • Shionogi
  • Shiyu Capital
  • Sinobioway Cell Therapy
  • Sinobioway Group
  • Sino-Singapore Chongqing Connectivity Private Equity Fund Management
  • Sirona Capital
  • Smilegate Investment
  • SNU Bio Angel
  • Sorrento Therapeutics
  • SpringWorks Therapeutics
  • Square One Bank
  • SR One
  • Stage Cell Therapeutics 
  • Stanford University
  • Statcom 
  • Steam Athena Capital
  • Stratophase 
  • SunTerra Capital
  • Super-T Cell Cancer Company
  • Suzhou Oriza Holdings
  • Symvivo
  • Syncona
  • SyndicateRoom
  • Syno Capital
  • Synthace 
  • Syracuse Biopharma
  • T. Rowe Price Group
  • Tactiva Therapeutics
  • Taiho Ventures and Wu Capital
  • Takara Bio
  • Takeda Pharmaceutical
  • Takeda Ventures
  • Targazyme
  • Tavistock Group
  • TC BioPharm
  • T-Cell Factory 
  • TCR2 Therapeutics
  • TCRCure Biopharma
  • Technology Strategy Board
  • Tekla Capital Management
  • Temasek Holdings
  • Teneobio
  • Tessa Therapeutics
  • The Beijing Pregene Science and Technology
  • The Invus Group
  • The Pregene (ShenZhen) Biotechnology
  • The University of Texas Health Science Center
  • Thermo Fisher Scientific
  • Third Rock Ventures
  • Tianjin Mycure Medical Technology
  • TILT Biotherapeutics
  • Timmune Biotech
  • Tmunity Therapeutics
  • TNK Therapeutics
  • Touchstone Innovations
  • TPG
  • TrakCel
  • Transgene
  • Transposagen Biopharmaceuticals
  • Trout Capital 
  • Tscan Therapeutics
  • Two River
  • TxCell 
  • Union Stem Cell & Gene Engineering
  • Universal Cells
  • University of California
  • University of Montreal
  • University of Oxford
  • University of Pennsylvania
  • Unum Therapeutics
  • Utrecht Holdings
  • UWELL Biopharma
  • V Foundation
  • venBio
  • Venrock
  • Versant Ventures
  • Vi Ventures
  • Vida Ventures
  • Viking Global Investors
  • ViroMed Laboratories
  • Vitruvian Networks
  • Vivo Capital
  • Vor Biopharma
  • Weill Cornell Medical College
  • Wellcome Trust 
  • Wellington Management
  • Wellington Partners
  • Wellington Zhaotai Therapies
  • Westlake Ventures
  • Westlake Village BioPartners
  • WH Partnership
  • White Rock Capital Management
  • WindMIL Therapeutics
  • Woodford Investment Management
  • Wugen
  • Wuhan Bio-Raid Biotechnology
  • Wuhan Dangdai Science and Technology Industries Group
  • Wuhan Sian Medical Technology
  • WuXi AppTec
  • Xi'An Yufan Biotechnology
  • Xiangxue Life Sciences
  • Xiangxue Pharmaceutical
  • Xinyi Capital
  • Yake Biotechnology
  • Yipu Capital
  • YuanMing Capital
  • Yuanyi Biotechnology
  • Zelluna Immunotherapy 
  • Zhejiang HUACHENG Holdings Group
  • Zhejiang Huahai Pharmaceutical 
  • Ziopharm Oncology
Note: Product cover images may vary from those shown
4 of 4

 

 

Loading
LOADING...

Adroll
adroll